ASH2018 注目テーマ Late-Breaking Abstracts Session #2

移植非適応の高齢初発MM患者に対し
ダラツムマブ＋Rd療法がPFSを延長 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Thierry Facon（Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France）